Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$1B |
| 2 |
MHFI
MCGRAW-HILL FINANCIAL INC COM
MHFI
|
+$539M |
| 3 |
Alibaba
BABA
|
+$476M |
| 4 |
AGN
Allergan plc
AGN
|
+$464M |
| 5 |
Perrigo
PRGO
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$777M |
| 2 |
Merck
MRK
|
+$766M |
| 3 |
AGN
Allergan Inc
AGN
|
+$573M |
| 4 |
SLB Ltd
SLB
|
+$551M |
| 5 |
TJX Companies
TJX
|
+$521M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.12% |
| 2 | Consumer Discretionary | 14.46% |
| 3 | Technology | 12.11% |
| 4 | Communication Services | 11.75% |
| 5 | Financials | 9.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VR
426
DELISTED
Validus Hold Ltd
VR
| $22.8M | 0.02% |
549,568
-181,482
| -25% | -$7.33M |
|
|
AGTC
427
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $22.7M | 0.02% |
1,080,217
-4,303
| -0.4% | -$87.6K |
|
428
Helmerich & Payne
HP
$3.35B
| $21.7M | 0.02% |
322,488
-616,034
| -66% | -$48M |
|
429
Chord Energy
CHRD
$7.64B
| $21.7M | 0.02% |
1,313,234
-5,302
| -0.4% | -$131K |
|
|
ENDP
430
CALL
DELISTED
Endo International plc
ENDP
| $21.6M | 0.02% |
300,000
| – | – |
|
|
CMRX
431
DELISTED
Chimerix, Inc.
CMRX
| $21.4M | 0.02% |
530,994
-22,135
| -4% | -$750K |
|
|
PFPT
432
DELISTED
Proofpoint, Inc.
PFPT
| $21.4M | 0.02% |
442,990
-17,032
| -4% | -$729K |
|
433
Plains GP Holdings
PAGP
$5.27B
| $21.2M | 0.02% |
310,263
-720,310
| -70% | -$51.2M |
|
434
Kosmos Energy
KOS
$1.48B
| $21M | 0.02% |
2,507,105
-219,909
| -8% | -$1.96M |
|
435
United Natural Foods
UNFI
$3.05B
| $21M | 0.02% |
271,691
+93,022
| +52% | +$6.58M |
|
|
TAHO
436
DELISTED
Tahoe Resources Inc
TAHO
| $20.6M | 0.02% |
1,483,468
-60,960
| -4% | -$1.03M |
|
|
HMHC
437
DELISTED
Houghton Mifflin Harcourt Company
HMHC
| $19.9M | 0.02% |
961,410
+17,798
| +2% | +$355K |
|
|
CSII
438
DELISTED
Cardiovascular Systems, Inc.
CSII
| $19.9M | 0.02% |
661,603
-14,067
| -2% | -$402K |
|
439
Neurocrine Biosciences
NBIX
$18.3B
| $19.7M | 0.02% |
+882,155
| New | +$16.7M |
|
440
Albemarle
ALB
$13.4B
| $19.3M | 0.02% |
320,749
-1,834,136
| -85% | -$108M |
|
|
ISBC
441
DELISTED
Investors Bancorp, Inc.
ISBC
| $18.9M | 0.02% |
1,686,653
+987,202
| +141% | +$10.5M |
|
|
CIM
442
Chimera Investment
CIM
$1.06B
| $18.7M | 0.02% |
391,918
-55,016
| -12% | -$2.66M |
|
|
RMP
443
DELISTED
Rice Midstream Partners LP
RMP
| $18.6M | 0.02% |
+1,108,120
| New | +$18.2M |
|
444
Kinross Gold
KGC
$28.1B
| $18.4M | 0.02% |
6,508,608
-309,180
| -5% | -$867K |
|
|
PKY
445
DELISTED
Parkway, Inc.
PKY
| $18.2M | 0.02% |
989,197
+50,785
| +5% | +$968K |
|
|
PTLA
446
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $18.2M | 0.02% |
641,299
-706
| -0.1% | -$19.6K |
|
447
PUT
Ionis Pharmaceuticals
IONS
$8.95B
| $17.6M | 0.02% |
285,000
| – | – |
|
|
GWPH
448
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $17.5M | 0.02% |
+258,914
| New | +$18.9M |
|
449
Agios Pharmaceuticals
AGIO
$2.09B
| $17.5M | 0.02% |
156,277
-81,148
| -34% | -$7.25M |
|
|
CYT
450
DELISTED
CYTEC INDS INC
CYT
| $17.2M | 0.02% |
372,195
-77,738
| -17% | -$3.62M |
|
Similar funds
Jennison Associates's Q4 2014 Portfolio in Review
As of Q4 2014, Jennison Associates held 806 positions worth $107B, down 0.8% from $108B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates withdrew a net $3.79B in Q4 2014, closing 91 positions and reducing 351 holdings. Its most notable exit was Oneok, an estimated $184M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 19% a quarter earlier, followed by Consumer Discretionary and Technology.
Against the trend, Jennison Associates opened a new position in Shire pic worth $1B.
- Jennison Associates's largest Q4 2014 buy was Shire pic: 4,721,078 shares worth $1B.
- Jennison Associates added most to Alibaba in Q4 2014, an estimated $476M increase.
- Jennison Associates's biggest Q4 2014 reduction was Alphabet (Google) Class C, cutting an estimated $777M.
- Jennison Associates fully exited Oneok in Q4 2014, selling an estimated $184M.
- Jennison Associates's ten largest holdings make up 20% of its $107B portfolio in Q4 2014.
- Jennison Associates opened 89 new positions and closed 91 in Q4 2014.
- Jennison Associates's portfolio value fell 0.8% quarter-over-quarter to $107B.
Based on Jennison Associates's 13F filing for Q4 2014, filed 6 Feb 2015.